Literature DB >> 31579333

<Editors' Choice> Renewed Japanese spirometric reference variables and risk stratification for postoperative outcomes in COPD patients with resected lung cancer.

Yu Okada1, Naozumi Hashimoto1, Shingo Iwano2, Koji Kawaguchi3, Takayuki Fukui3, Koji Sakamoto1, Kenji Wakai4, Kohei Yokoi3, Yoshinori Hasegawa1.   

Abstract

Although the lower limit of normal (LLN) of FEV1/FVC detects at-risk patients for postoperative outcomes among Japanese chronic obstructive pulmonary disease (COPD) patients with resected lung cancer, there was a lack of a Japanese reference equation to calculate the LLN of FEV1/FVC. Renewed Japanese spirometric reference variables might enable us to verify clinical impact of the LLN of FEV1/FVC among the Japanese population. To evaluate the clinical impact of the LLN of FEV1/FVC by using this renewed reference, data were retrospectively analyzed from 609 newly diagnosed lung cancer patients who had undergone thoracic surgery between 2006 and 2011. The combined assessment of the 0.70 fixed ratio and the LLN of the FEV1/FVC ratio classified the 609 subjects into the COPD (214 subjects), non-COPD (337 subjects), and in-between (58 subjects) groups, respectively. All of the relative odds ratios (ORs) of postoperative outcomes for the comparison between the in-between and non-COPD groups did not show significant confidence intervals (CIs). On the other hand, the adjusted ORs of postoperative outcomes for the COPD group versus the non-COPD group were 2.840 (95% CI: 1.824-4.421) for prolonged oxygen therapy (POT), 1.836 (95% CI: 1.166-2.890) for prolonged postoperative stays, and 1.637 (95% CI: 1.007-2.663) for combined complications. Adjusted comparisons of POT between the in-between and COPD groups also showed a significant relative OR of 2.984 (95% CI: 1.447-6.153). A standardized assessment of the LLN of FEV1/FVC by a renewed Japanese spirometric reference provides risk stratification for postoperative outcomes in the population.

Entities:  

Keywords:  Japanese; chronic obstructive lung disease; lower limit of normal; lung cancer; thoracic surgery

Mesh:

Year:  2019        PMID: 31579333      PMCID: PMC6728190          DOI: 10.18999/nagjms.81.3.427

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  20 in total

1.  Inspiratory capacity as a preoperative assessment of patients undergoing thoracic surgery.

Authors:  Masaki Matsuo; Naozumi Hashimoto; Noriyasu Usami; Kazuyoshi Imaizumi; Kenji Wakai; Tsutomu Kawabe; Kohei Yokoi; Yoshinori Hasegawa
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-03

2.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

3.  Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.

Authors:  Peter Lange; Bartolome Celli; Alvar Agustí; Gorm Boje Jensen; Miguel Divo; Rosa Faner; Stefano Guerra; Jacob Louis Marott; Fernando D Martinez; Pablo Martinez-Camblor; Paula Meek; Caroline A Owen; Hans Petersen; Victor Pinto-Plata; Peter Schnohr; Akshay Sood; Joan B Soriano; Yohannes Tesfaigzi; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2015-07-09       Impact factor: 91.245

4.  ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy).

Authors:  A Brunelli; A Charloux; C T Bolliger; G Rocco; J-P Sculier; G Varela; M Licker; M K Ferguson; C Faivre-Finn; R M Huber; E M Clini; T Win; D De Ruysscher; L Goldman
Journal:  Eur Respir J       Date:  2009-07       Impact factor: 16.671

5.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

6.  The need to change the method for defining mild airway obstruction.

Authors:  P H Quanjer; P L Enright; M R Miller; J Stocks; G Ruppel; M P Swanney; R O Crapo; O F Pedersen; E Falaschetti; J P Schouten; R L Jensen
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

7.  Clinical impact of the lower limit of normal of FEV1/FVC on survival in lung cancer patients undergoing thoracic surgery.

Authors:  Asuka Matsuzaki; Naozumi Hashimoto; Shotaro Okachi; Tetsuo Taniguchi; Koji Kawaguchi; Takayuki Fukui; Kenji Wakai; Kohei Yokoi; Yoshinori Hasegawa
Journal:  Respir Investig       Date:  2015-12-21

8.  The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection.

Authors:  Rihong Zhai; Xiaojin Yu; Andrea Shafer; John C Wain; David C Christiani
Journal:  Chest       Date:  2014-02       Impact factor: 9.410

Review 9.  Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes.

Authors:  Stacy Raviv; Keenan A Hawkins; Malcolm M DeCamp; Ravi Kalhan
Journal:  Am J Respir Crit Care Med       Date:  2010-12-22       Impact factor: 21.405

10.  The ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary disease.

Authors:  Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Carolyn L Rochester; H Klar Yaggi; Thomas M Gill
Journal:  Am J Respir Crit Care Med       Date:  2009-12-17       Impact factor: 21.405

View more
  2 in total

1.  Associations Between Morphological Phenotypes of COPD and Clinical Characteristics in Surgically Resected Patients with COPD and Concomitant Lung Cancer.

Authors:  Yusuke Suzuki; Yoshiaki Kitaguchi; Fumika Ueno; Yunden Droma; Norihiko Goto; Takumi Kinjo; Yosuke Wada; Masanori Yasuo; Masayuki Hanaoka
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-06-21

Review 2.  The Importance of Appropriate Diagnosis in the Practical Management of Chronic Obstructive Pulmonary Disease.

Authors:  Naozumi Hashimoto; Keiko Wakahara; Koji Sakamoto
Journal:  Diagnostics (Basel)       Date:  2021-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.